SCHEMBL1844348

SCHEMBL1844348

CC(C)(C)OC(=O)n1cc(CO)cn1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 1/20 0.41
SCD O00767 1/20 0.40
MGLL Q99685 1/20 0.36
GPR119 Q8TDV5 2/20 0.35
FAAH O00519 1/20 0.35
ELANE P08246 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.33
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
NR1H2 P55055 2/20 0.33
BCHE P06276 1/20 0.33
HTR6 P50406 1/20 0.32
GABRG2 P18507 1/20 0.32
GABRB3 P28472 1/20 0.32
GABRA5 P31644 1/20 0.32
HTT P42858 1/20 0.32
ATM Q13315 1/20 0.32
ABCB1 P08183 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2546394 0.88 ROCK2 (0.40) ROCK2SCDMGLLGPR119FAAH
SCHEMBL18617132 0.87 ROCK2 (0.41) ROCK2SCDMGLLGPR119FAAH
SCHEMBL21121081 0.87 ROCK2 (0.41) ROCK2SCDMGLLGPR119FAAH
SCHEMBL429428 0.86 ROCK2 (0.43) ROCK2SCDMGLLGPR119FAAH
SCHEMBL13354632 0.86 GABRA1 (0.43) ROCK2SCDMGLLGPR119FAAH
SCHEMBL23703179 0.83 ROCK2 (0.41) ROCK2SCDMGLLGPR119FAAH
SCHEMBL20029212 0.82 SCD (0.47) ROCK2SCDMGLLBCHE
SCHEMBL429675 0.82 NR1H2 (0.43) ROCK2SCDMGLLGPR119ALDH1A1
SCHEMBL23075458 0.81 CYP17A1 (0.49) ROCK2SCDMGLLGPR119
SCHEMBL23076353 0.80 KDM1A (0.40) ROCK2SCDELANE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12435092-B2 Substituted imidazo[1,2-A]quinazolines as inhibitors of PARG 858 THERAPEUTICS, INC. (US) 2025-10-07 US disclosed
US-20250154169-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING REMIX THERAPEUTICS INC. 2025-05-15 US disclosed
EP-4526304-A1 INHIBITORS OF PARG 858 Therapeutics, Inc. (US) 2025-03-26 EP disclosed
US-20240352018-A1 SUBSTITUTED IMIDAZO[1,2-a]QUINAZOLINES AND IMIDAZO[1,2-a]PYRIDO[4,3-e]PYRIMIDINES AS INHIBITORS OF PARG 858 THERAPEUTICS, INC. 2024-10-24 US disclosed
CN-118302426-A Compounds and methods for modulating splicing 雷密克斯医疗公司 2024-07-05 CN disclosed
US-11986471-B2 Compounds and methods of use TANGO THERAPEUTICS, INC. (US) 2024-05-21 US disclosed
WO-2024084447-A2 AZETIDINYL BENZOXAZOLE COMPOUNDS AND THEIR USE AS MER AND AXL INHIBITORS DONG-A ST CO., LTD. (KR) 2024-04-25 WO disclosed
EP-4126855-B1 COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTIONS HOFFMANN LA ROCHE (CH) 2024-04-24 EP disclosed
US-20240101531-A1 PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS XENON PHARMACEUTICALS INC. (CA) 2024-03-28 US disclosed
US-11939335-B2 Substituted imidazo[1,2-a]quinazolines and imidazo [1,2-a]pyrido[4,3-e]pyrimidines as inhibitors of PARG 858 THERAPEUTICS, INC. (US) 2024-03-26 US disclosed
EP-2172450-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF Mitsubishi Tanabe Pharma Corporation (JP) 2010-04-07 EP disclosed
US-20100041656-A1 Novel amide derivatives and medicinal use thereof NAKAMURA MITSUBARU 2010-02-18 US disclosed
US-20080194640-A1 Optically Active Tetrahydronaphthalene Derivative MITSUBISHI TANABE PHARMA CORPORATION (JP) 2008-08-14 US disclosed
US-20080194640-A1 Optically Active Tetrahydronaphthalene Derivative MITSUBISHI TANABE PHARMA CORPORATION (JP) 2008-08-14 US disclosed
US-20080194640-A1 Optically Active Tetrahydronaphthalene Derivative MITSUBISHI TANABE PHARMA CORPORATION (JP) 2008-08-14 US disclosed
EP-1852431-A1 OPTICALLY ACTIVE TETRAHYDRONAPHTHALENE DERIVATIVE MITSUBISHI PHARMA CORPORATION (JP) 2007-11-07 EP disclosed
EP-1852431-A1 OPTICALLY ACTIVE TETRAHYDRONAPHTHALENE DERIVATIVE MITSUBISHI PHARMA CORPORATION (JP) 2007-11-07 EP disclosed
US-20040138223-A1 Novel amide derivatives and medicinal use thereof ugs MITSUBISHI TANABE PHARMA CORPORATION (JP) 2004-07-15 US disclosed
EP-1318140-A1 NOVEL AMIDE DERIVATIVES AND MEDICINAL USE THEREOF UGS Mitsubishi Pharma Corporation (JP) 2003-06-11 EP disclosed
WO-1997041128-A1 3-PYRAZOLIOMETHYLCEPHEM COMPOUNDS AS ANTIMICROBIAL AGENTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1997-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12435092-B2 Substituted imidazo[1,2-A]quinazolines as inhibitors of PARG PARG, PLG, PTGIS ROCK2 995/4885SCD 4286/4885MGLL 1942/4885
US-11986471-B2 Compounds and methods of use XDH, F12, LPXN ROCK2 2287/4885SCD 4529/4885MGLL 1999/4885
US-20080194640-A1 Optically Active Tetrahydronaphthalene Derivative C3AR1, C5AR1, C5AR2 ROCK2 4452/4885SCD 3448/4885MGLL 4298/4885
US-20240101531-A1 PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS KCNA1, KCNB1, KCNB2 ROCK2 3095/4885SCD 2713/4885MGLL 3584/4885
US-20250154169-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING RBM17, SNRPA, SNRPA1 ROCK2 3891/4885SCD 978/4885MGLL 3186/4885
US-20240352018-A1 SUBSTITUTED IMIDAZO[1,2-a]QUINAZOLINES AND IMIDAZO[1,2-a]PYRIDO[4,3-e]PYRIMIDINES AS INHIBITORS OF PARG PARG, PLG, PARN ROCK2 1787/4885SCD 4211/4885MGLL 2880/4885
US-20100041656-A1 Novel amide derivatives and medicinal use thereof C5AR1, C5AR2, C3AR1 ROCK2 1698/4885SCD 1765/4885MGLL 3774/4885
US-11939335-B2 Substituted imidazo[1,2-a]quinazolines and imidazo [1,2-a]pyrido[4,3-e]pyrimidines as inhibitors of PARG PARG, PTGIS, PLG ROCK2 1731/4885SCD 4252/4885MGLL 3047/4885
US-20040138223-A1 Novel amide derivatives and medicinal use thereof ugs C5AR1, C5AR2, C1S ROCK2 2647/4885SCD 1339/4885MGLL 2322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.